Ann: First patent granted for Deoxymab-nanoparticles, page-20

The 200 doesn't care about FA per se - it just tells you about what buyers are doing and the longer term trend shifting - once it closes above and then holds it it's usually more a case of could'a should'a would'a ...

But the FA seems to match the trend - a pretty hot tech licensed out of a top university, in a super hot space with plenty of large deals of late even on pre-clinical assets, recently shored up funding so that's secured, 2 ultra's in the registry, Roche / Genentech being the number 1 cancer drug provider in the world - i doubt you get their ex VP development & CMO a long with their head of partnering, business development because they thought a change of scenery with something flimsy and a tiny biotech "down under" was a logical next step. Not to forget the CEO sold Chemgenex to Cephalon for a few hundred million.